1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Systemic Lupus Erythematosus (SLE): KOL Insight 2017

Systemic Lupus Erythematosus (SLE): KOL Insight 2017

  • July 2017
  • ID: 5175259
  • Format: PDF
  • By Firstword Pharma

Summary

Table of Contents

Will novel therapies revolutionise the treatment of SLE?

With the approval of GSK’s Benlysta (belimumab) came the dawn of targeted therapy in the treatment of systemic lupus erythematosus (SLE). Roche’s Rituxan/MabThera (rituximab), now experiencing biosimilar competition in Europe, is also used off-label. Despite these advances significant unmet need remains in the treatment of SLE. Novel products are on the horizon, including anifrolumab (BMZ/AstraZeneca), forigerimod (ImmunPharma) and voclosporin (Aurinia Pharma), but challenges in the development of novel SLE treatments mean that nothing should be taken for granted. Learn how KOLs see the market evolving, and how they expect developers to differentiate their pipeline therapies in KOL Insight: Systemic Lupus Erythematosus (SLE). Twelve North American and European KOLs give their insight on one marketed product, one off-label product and 10 pipeline programmes. KOLs also provide their candid views on the potential for novel mechanisms of action.


Take a tour of the report now:

Methodology >
Research Objectives >
Questions Asked >
See the Multiple Myeloma therapies covered >
Find out who the 6 US and 6 European KOLs are >
Sample Pages >

Top Takeaways


  • SLE is a highly heterogenic condition, and patients frequently present with an array of clinical manifestations and of varying severity. Do KOLs believe there is a need for conclusive diagnostic tests, and is swift and accurate diagnosis problematic? 
  • The treatment of SLE relies on a wide range of drugs, but unmet needs remain. What do KOLs think of the current armamentarium of treatments, there safety, efficacy and long-term tolerability, and what is the most significant unmet need when it comes to pharmacological intervention? 
  • What does Benlysta (belimumab) bring to the treatment of SLE, and do KOLs have any concerns about its use? Benlysta was the first targeted therapy approved for the treatment of SLE, but how does it fair against other treatments, including off-label Rituxan/MabThera (rituximab; Roche). Moreover, what concerns remain about the use of Benlysta, and how do KOLs believe these can be overcome? 
  • Will a subcutaneous formulation of Benlysta drive growth? Since its launch in 2011, uptake of Benlysta has been slow, so will the availability of a subcutaneous formulation boost prescribing, or will efficacy and safety concerns remain? 
  • The late-stage development pipeline comprises a number of targeted therapies, but which ones excite the most? Foremost amongst these is the anti-interferon-alpha mAb, anifrolumab. While early-stage data looked promising , do KOLs expect the Phase III studies to confirm these earlier findings, and how will this impact approval and launch? Moreover, how are other late-stage pipeline programmes shaping up, and which programmes are KOLs most excited about? 
  • The mid-stage development pipeline is in rude health, but do KOLs expect any of these programmes to move into later-stage testing? A number of novel mAbs are in Phase II development, many of them possessing novel modes of action. But will they offer a welcome addition to the current treatment arsenal, or doe safety concerns, particularly with long-term use, remain? 
  • Clinical attrition in the SLE pipeline remains an issue, but what do KOLs believe needs to be done to stop the rot? Study design is considered to be a significant contributing factor to failure rates, so what do KOLs believe needs to be done in relation to endpoint selection, comparator drug selection and study duration, and will these changes drive future R&D investment in SLE? 
  • Will the development of biomarkers support selective use of the expanding array of targeted therapies? Given the expense of targeted therapies and the time taken to achieve clinical efficacy, will the use of biomarkers be crucial to ensuring their rational use? In the longer term, are biomarkers expected to emerge that will support diagnosis, monitoring, and prediction of future disease progression? 

Quotes
“If you look at the data, it [Benlysta] is not [that impressive]. With BLISS-76 there was no difference. I’m not sure I can actually say more than that, but there was no difference. So really it’s quite weak data supporting that drug.”North American Key Opinion Leader


“Obviously this is awaited with great interest. We haven’t seen the big Phase III trials yet. We need more information before we can make reasonable and sensible guesses, before we can really generate ideas as to whether or not this drug is going to be really good and exactly how it’s going to be used.“EU Key Opinion Leader

Sample of therapies covered

Marketed Therapies

Benlysta (belimumab; HGS/GSK)
Rituxan/MabThera (rituximab; Roche – OFF LABEL)

Pipeline Therapies
Anifrolumab (BMZ/AstraZeneca)
Forigerimod (ImmunPharma)
Abatacept (BMS)
Voclosporin (Aurinia Pharma)
BIIB 059 (Biogen)
Obinutuzumab (Roche)
Dapirolizumab pegol (UCB)
Ustekinumab (Janssen Biotech)
Theralizumab (TheraMab)
Baricitinib (Eli Lilly)

Sample of KOLs interviewed

KOLs from North America


  • Mary Anne Dooley. Adjunct Professor of Medicine, University of North Carolina Kidney Center and Division of Nephrology & Hypertension, University of North Carolina, Chapel Hill School of Medicine. 
  • Bevra H. Hahn. Chief, Rheumatology and Arthritis, and Professor and Vice Chair, School of Medicine, University of California, Los Angeles.
  • Roberto Caricchio. Director and Associate Professor, Medicine, and Associate Professor, Microbiology and Immunology, Temple Lupus Clinic, Lewis Katz School of Medicine, Temple University, Philadelphia. 
  • Petros Efthimiou. Associate Chief of Rheumatology, New York Presbyterian-Brooklyn Methodist Hospital, New York.
  • Murray Urowitz. Director and Professor of Medicine, Centre for Prognosis Studies in the Rheumatic Diseases, Krembil Research Institute, University of Toronto, Canada
  • Victoria Werth. Professor of Dermatology and Medicine, University of Pennsylvania School of Medicine, Philadelphia. 
  • KOLs from Europe
  • Venkat Reddy. MRCP, Senior Research Associate, University College London, Centre for Rheumatology, Bloomsbury Rheumatology Unit, Chelsea and Westminster NHS Trust, London, UK. 
  • David Isenberg. Professor and Consultant, Department of Rheumatology, University College London Hospitals NHS Foundation Trust, London, UK. 
  • Nathalie Costedoat-Chalumeau. Professor, AP-HP, Centre de Référence National Pour le Lupus Systémique et le syndrome des Antiphospholipides, Service de Médecine Interne, Hôpital Pitié-Salpêtrière, Paris, France. 
  • Raphaèle Seror. Professor, Rheumatology Unit, Bicêtre University Hospital, Le Kremlin Bicetre, France. 
  • Ricard Cervera. Senior Consultant Physician and Head at the Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Head of the Research Team on Systemic Autoimmune Diseases at the Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, and Professor at the Department of Medicine, Universitat de Barcelona. Barcelona, Spain. 
  • Ronald Van Vollenhoven. Professor of Rheumatology at the University of Amsterdam’s Faculty of Medicine, Head of the Clinical Immunology and Rheumatology department at Amsterdam’s Academic Medical Center and Head of the Rheumatology department at the VU University Medical Center. 

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Global Cancer Immunotherapy Market Opportunity, Dosage, Price & Clinical Trials Insight 2026

Global Cancer Immunotherapy Market Opportunity, Dosage, Price & Clinical Trials Insight 2026

  • $ 4000
  • February 2020

"Global Cancer Immunotherapy Market Opportunity, Dosage, Price & Clinical Trials Insight 2026" Report Highlights:• Global Cancer Immunotherapy Market Opportunity: > US$ 200 Billion • Cance ...

House Dust Mite Allergy - Pipeline Review, H1 2020

House Dust Mite Allergy - Pipeline Review, H1 2020

  • $ 2000
  • January 2020

House Dust Mite Allergy - Pipeline Review, H1 2020SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide House Dust Mite Allergy - Pipeline Review, H1 2020, provides an overview of the ...

Transforming Growth Factor Beta 1 - Pipeline Review, H1 2020

Transforming Growth Factor Beta 1 - Pipeline Review, H1 2020

  • $ 3500
  • January 2020

Transforming Growth Factor Beta 1 - Pipeline Review, H1 2020SummaryAccording to the recently published report ’Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H1 2020’; Transforming Growth ...


ref:plp2017

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on